Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Semin Nephrol. 2022 May;42(3):151286. doi: 10.1016/j.semnephrol.2022.10.012. Epub 2022 Nov 17.
Acute kidney injury (AKI) is a highly prevalent, heterogeneous syndrome, associated with increased short- and long-term mortality. A multitude of different factors cause AKI including ischemia, sepsis, nephrotoxic drugs, and urinary tract obstruction. Upon injury, the kidney initiates an intrinsic repair program that can result in adaptive repair with regeneration of damaged nephrons and functional recovery of epithelial activity, or maladaptive repair and persistence of damaged epithelial cells with a characteristic proinflammatory, profibrotic molecular signature. Maladaptive repair is linked to disease progression from AKI to chronic kidney disease. Despite extensive efforts, no therapeutic strategies provide consistent benefit to AKI patients. Since kidney biopsies are rarely performed in the acute injury phase in humans, most of our understanding of AKI pathophysiology is derived from preclinical AKI models. This raises the question of how well experimental models of AKI reflect the molecular and cellular mechanisms underlying human AKI? Here, we provide a brief overview of available AKI models, discuss their strengths and limitations, and consider important aspects of the AKI response in mice and humans, with a particular focus on the role of proximal tubule cells in adaptive and maladaptive repair.
急性肾损伤 (AKI) 是一种普遍存在且具有异质性的综合征,与短期和长期死亡率的增加相关。许多不同的因素可导致 AKI,包括缺血、脓毒症、肾毒性药物和尿路梗阻。在损伤后,肾脏启动内在修复程序,可导致适应性修复,即受损肾单位的再生和上皮功能的恢复,或导致适应性修复和受损上皮细胞的持续存在,伴有特征性的促炎、促纤维化分子特征。适应性修复与 AKI 向慢性肾脏病的疾病进展有关。尽管进行了广泛的努力,但没有治疗策略能为 AKI 患者提供一致的益处。由于在人类急性损伤阶段很少进行肾活检,因此我们对 AKI 病理生理学的大部分理解都来自于临床前 AKI 模型。这就提出了一个问题,即 AKI 模型在多大程度上反映了人类 AKI 背后的分子和细胞机制?在这里,我们简要概述了现有的 AKI 模型,讨论了它们的优缺点,并考虑了 AKI 反应在小鼠和人类中的重要方面,特别关注近端肾小管细胞在适应性和适应性修复中的作用。